20002022

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr Miles De Blasio is a Mid-Career Researcher and an emerging leader with a clear upward career trajectory. He leads Integrative Physiology in the Heart Failure Pharmacology laboratory in the Drug Discovery Biology (DDB) theme at Monash Institute of Pharmaceutical Sciences (MIPS). He holds an adjunct Honorary Research Collaborator position at the Baker Heart and Diabetes Institute and Dept of Pharmacy (Monash Uni) and an Honorary Research Fellow of Department of Pharmacology at Monash.

Dr De Blasio completed his PhD in 2004 (Uni Adelaide) where he studied the endocrine and metabolic basis of diabetes and obesity after fetal growth restriction. He then spent 4-years in industry with the Australian Pork Cooperative Research Centre (CRC) before moving to the University of Cambridge (UK) to undertake a very successful post-doctoral research project investigating fetal leptin administration on lung and heart development. Dr De Blasio is well-recognised for his contributions to the fetal and postnatal physiology field.

In 2014 he returned to Australia and was recruited to the Baker Heart and Diabetes Institute by Prof Rebecca Ritchie (now Drug Discovery Biology Theme leader at Monash MIPS), to investigate new treatments for diabetic cardiomyopathy in pre-clinical models of diabetes; representing a significant change of research direction. In 2020, he moved to Monash University Institute of Pharmaceutical Sciences (MIPS) where he is now the lead researcher for the Heart Failure Pharmacology laboratory investigating new treatments for diabetic cardiomyopathy including the use of pharmacological agents and cardiac-selective gene therapies to target pathways involved in cardioprotection. This includes the hexosamine-biosynthesis pathway, particularly O-GlcNAcylation of proteins, the IGF1R-PI3K pathway and the cardiac adiponectin signalling pathway. He has an overarching vision to make significant contributions to the development of novel therapies for diabetic cardiomyopathy.

His track record to 2014 was investigating the fetal origins of obesity and diabetes in large animal models (sheep) and clinical trials (MiG and ACHOIS RCTs). He has been a CI on three NHMRC project grants investigating interventions for insulin resistance, beta-cell plasticity and diabetic cardiomyopathy and has obtained >$4million in funding as CI or named investigator. He has considerable experience with in vivo pre-clinical models of diabetes and metabolic syndrome, and design and administration of pharmaceutical and cardiac-selective gene therapies in vivo and in vitro, having published 60 career papers (34 in last 5 years). His research parameters indicate his research is high impact in the field (>2500 citations, >75% Q1 Journals, FWCI=1.71, world average=1, June 2021). He displays outstanding leadership qualities having supervised 9 PhD and 13 Honours students to completion since 2007.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

External positions

Baker Honorary Researcher (Collaborator), Baker Heart and Diabetes Institute

2020 → …

Research area keywords

  • Diabetic Complications
  • novel therapeutics
  • adiponectin
  • Pre-clinical studies
  • diastolic dysfunction
  • Diabetes
  • Cardiomyopathies
  • Clinical Trials

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or